/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | FMSFresenius Medical Ca |
|---|---|
| Last close | $22.95close 2026-11-09 |
| Change % | -1.92%close 2026-11-09 |
| Market cap | no share count |
| P/E | no EPS filed |
| Revenue | $5.3B⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenues As ofFY ending 2014-12-31 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | 5.9%FY to 2014-12-31, older period |
| Net income | $1.2B⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2016-12-31 Filing20-F · 0001047469-17-000816 · filed 2017-02-22 Open the filing on EDGAR →Open the XBRL payload →CiteFresenius Medical Care AG (FMS), us-gaap:NetIncomeLoss: 1,243,267,000 USD, fiscal year ended 2016-12-31. Form 20-F, accession 0001047469-17-000816, filed 2017-02-22. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0001333141/us-gaap/NetIncomeLoss.json |
| Net margin | periods differ |
| EPS (diluted) | no EPS filed |
| Piotroski F-ScoreUNVALIDATED | 5FY to 2014-12-31, older period |
| Altman Z-ScoreUNVALIDATED | 1.31FY to 2014-12-31, older period |
| Beneish M-ScoreUNVALIDATED | -2.58FY to 2014-12-31, older period |
| Next earnings | — |